Kornimate/medical-research-clean huggingface dataset:
a study using cone beam ct for head and neck cancer

Conditions: Head and Neck Cancer

Summary: cone beam ct (computed tomography) is a developing technology which allows ct images to be obtained while a patient is on the radiation treatment table.(a ct scan uses x-rays to produce detailed pictures of structures in the body.) in this study, cone beam ct scans will be obtained before individual radiation treatment sessions for head and neck cancer. the information gathered from these scans will be used by the researchers to look at patient movement as well as changes in the amount of normal and tumor tissue throughout the course of radiation therapy. the researchers will use this information to create hypothetical radiation treatment plans, which will be used as the basis for future research. the cone beam ct scan data will not be used to alter the actual radiation treatment of any of the patients enrolled on the study. in addition, tests of salivary output and swallowing and questionnaires about quality of life will be made to assess how the doses of radiation affect them.


Eligibility criteria:
inclusion criteria: * patients of all ages ≥18, both sexes, and all races will be included in this study. pregnant females will be excluded. no other special classes of subjects (i.e., prisoners) will be entered. * patients must be diagnosed with biopsy-proven squamous cell carcinoma of the head and neck. * patients must be recommended treatment with definitive radiation therapy with concurrent chemotherapy, but without prior surgical resection of the primary tumor or lymph nodes * patients must be recommended a treatment course of at least 30 radiation fractions * patients must sign an informed consent form approved for this purpose by the institutional review board (irb) of the university of michigan hospital indicating that they are aware that undergoing cone beam ct of the head and neck is voluntary and has potential risks. exclusion criteria: * patients must not have a history of prior radiation to the head or neck
prevention of delirium among elderly patients with hip fractures

Conditions: Delirium; Hip Fractures

Summary: objective: to evaluate the effect of care bundle on prevention of delirium among elderly patients with hip fractures. methods: a prospective randomized case control study was performed for 80 patients (≥65 years) with hip fractures treated surgically according to their ages and the type of fractures from march 1th of 2017 to june 30th of 2017．there were 11 males and 69 females, with the age of (79.3±7.84) years. confusion assessment method (cam) was applied to diagnose delirium after surgery, the subjects were randomized divided into experimental group (n=43) and control group (n=37). the parameters next were recorded and analyzed, including age, gender, type of fractures, type of internal instrument, amount of bleeding, time between injured to surgery, time length of operation, type of operation, vas, incidence of delirium, perioperative complications and adverse events.


Eligibility criteria:
inclusion criteria: * ≥65 years * with hip fractures * treated surgically exclusion criteria: * \<65 years * psychiatric history * icu post-operation * refuse to join this study * have delirium pre-operation

Keywords: hip fractures delirium aged care bundle
study using wst11 in patients with obstructing endobronchial non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: the aim of this study is to determine the dose of wst11 and light energy necessary to obtain desobstruction of the bronchial lumen using vascular targeted photodynamic therapy in obstructive non-small cell lung cancer.

this study is designed as a multicentre, exploratory phase iia, open label, single intravenous (iv) dose, escalating treatment regimen (treatment regimen = a single dose of wst11 associated with a particular laser light energy) with a one month follow-up. six escalating treatment regimens will be followed: 3 wst11 doses (5 mg/kg; 7.5 mg/kg and 10 mg/kg) combined with 2 light energies (200 joules/cm and 300 joules/cm) the patient will be treated under local anesthesia. the light is produced using a specific laser at a wavelength of 753 nm at a fixed power of 250 mw/cm and locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. the fiber illuminating diffusion length is fixed (2 cm).

Eligibility criteria:
inclusion criteria: * histologically proven lung cancer * inoperable * non-small cell cancer * partial or total bronchial obstruction responsible for functional signs * t1 to t4, n0-n3, m0-m1 * patients with functional signs: hemoptysis, infection, cough and, above all, dyspnea * contralateral metastases not representing a contraindication insofar as they do not represent a risk of impairment of respiratory function during treatment * the karnofsky index should be greater than or equal to 40 * patients should agree to and tolerate repeated bronchial endoscopy (a disadvantage of all endoscopic treatments) * male or female patients aged over 18 years, female patients should not be pregnant (menopause or contraception) * patients should have given their written consent to take part in the study exclusion criteria: * tracheal lesions and lesions affecting the carina tracheae * patients with painful bone metastases (not an absolute criterion since the extent of dyspnea is the decisive element) * patients with brain metastases * patients having undergone pneumonectomy * patients undergoing chemotherapy or radiotherapy or having undergone chemotherapy less than 4 weeks before the procedure or radiotherapy less than 4 weeks before the procedure * patients with risk of large vessel erosion or perforation resulting from lesion topography * in case of allergy to the photosensitizer * leukopenia (wbc\ 1.5 normal, fibrinogen \ 1.5 uln (upper limit of normal) * renal insufficiency * hepatic insufficiency * patients having already received 70 gy on the lesion * existing tracheoesophageal or bronchoesophageal fistula * emergency treatment of patients with severe acute respiratory distress caused by an obstructing endobronchial lesion

Keywords: non-small cell lung cancer lung cancer nsclc
multi-component breath alcohol intervention phase 3

Conditions: Alcohol Use; Alcohol Drinking; Drinking Behavior

Summary: this is the third stage of a three-stage, nih-funded study to develop and test a multi-modal intervention concerning blood/breath alcohol concentration for young adults who drink heavily. the multimodal intervention will be made up of brief telehealth counseling and psychoeducation and use of three existing mobile technologies. the brief counseling/psychoeducation and mobile technologies provide personalized feedback regarding blood or breath alcohol content. the long-term goal of use of these mobile technologies will be to facilitate moderate drinking. however, the main goals of the proposed research are to learn more about feasibility of our procedures, perceived value of the technologies and ease of use from the research participants' points of view. in this third stage of the study, the investigators will conduct a randomized controlled trial building on the formative research conducted in stages 1 and 2.


Eligibility criteria:
inclusion criteria: * be between the ages of 18-25 * be able to read english and complete study evaluations * at least occasional heavy episodic drinking (i.e., 4 or more drinks for women and 5 or more drinks for men) over the prior 30 days * frequent consumption of at least one alcoholic drink during a minimum of 12 days out of the prior 30 so that subjects will have multiple opportunities to use the moderate drinking technologies during the intervention period. exclusion criteria: * severe substance use disorder * be psychotic or otherwise severely psychiatrically disabled * report a history of a medical condition that would contraindicate the consumption of alcohol (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, and gastrointestinal disorders)
metabolic adaptation to diabetes

Conditions: Type 2 Diabetes

Summary: hypoglycemia or low blood sugar is a very serious complication that diabetics experience. this is of great concern because there is a lack of available information of how non insulin dependent diabetic mellitus patients (niddm) defend themselves against a low blood sugar. this is particularly disturbing since niddm patients are likely to require intensive treatment, and as a result, the risks of severe hypoglycemia to the niddm patient increase. the current proposal aims to provide information on how niddm patients can defend themselves against hypoglycemia, thus decreasing their risks for this severe complication.

there is very little data available on the neuroendocrine response to hypoglycemia in intensively treated (sulfonylurea or insulin) niddm patients. the data that are available on the neuroendocrine response to hypoglycemia in niddm patients were obtained under conditions following a single iv bolus of insulin or single sq regular insulin injection. the neuroendocrine response following a large iv bolus of insulin differs greatly from the clinical paradigm of a slow progression into hypoglycemia. therefore, clinically relevant data cannot be obtained from short experiments involving rapid changes in plasma glucose levels and insulinemia. furthermore, a comparison between neuroendocrine responses to hypoglycemia in niddm and normal man is not available due to the fact that glycemia has never been equally controlled. in short, virtually nothing is known about the neuroendocrine response to hypoglycemia in these subjects. this is of great concern as following the positive outcome of the kumamato study, large numbers of niddm subjects are going to receive intensive therapy with all its altendent risks of severe hypoglycemia. the kumamato study was a trial in niddm patients to determine if intensive therapy reduces tissue complications of diabetes. similar to the results of the diabetes control and complications trial in iddm patients the kumamato study proved that intensive therapy in niddm patients also prevents diabetic tissue complications. therefore, the goals of this study are 1) to define in greater detail how the body defends itself against hypoglycemia in niddm patients and 2) to determine if differing levels of insulin affect hypoglycemic counterregulation in niddm patients.

Eligibility criteria:
inclusion criteria: * healthy male and female subjects aged 30-65 years * male and female non-insulin-dependent diabetic patients, sulfonylurea and/or metformin aged 30-65 years exclusion criteria: * prior or current history of poor health * abnormal results following screening tests * pregnancy

Keywords: type 2 diabetes intensive therapy
how often are pharmacist recommendations followed by emergency physicians in emergency departments?

Conditions: Pharmacist Recommendations

Summary: clinical pharmacy has played a role in emergency departments (ed). the presence of pharmacists have been shown to reduce medication errors and improve the medication history taken at admission. in denmark a recent study revealed that clinical pharmacists identified medication problems in 25% of all admission to the ed, of which 47 % were considered to be serious. however, the pharmacist recommendations are of little value if they are not acknowledged or followed by the physicians. the aim of the present study was to analyze how often and under which circumstances the physicians made use of pharmaceutical recommendations in an ed with a mixed patient population with special attention to those recommendations, which were of significant or disastrous importance.


Eligibility criteria:
inclusion criteria: - all acute admissions to emergency department who were treated with one or more drugs exclusion criteria: - children less than 15 years.
maraviroc efficacy for hepatitis c

Conditions: Hepatitis C; Human Immunodeficiency Virus

Summary: this is a single-site, longitudinal, open-label, interventional study for evaluating the effect of maraviroc on hepatitis c viral levels in patients infected with both hepatitis c and human immunodeficiency virus (hiv) and taking antiretroviral therapy for hiv.

recently, in-vitro studies (experiments performed in a laboratory, not on a person) have demonstrated that maraviroc, a medication that is used in human immunodeficiency (hiv) therapy, appears to have significant hepatitis c antiviral effect, comparable to sofosbuvir-a potent anti-hepatitis c medication. in this study, the investigators will evaluate the antiviral effect of maraviroc on hepatitis c virus in people infected with both hepatitis c and hiv, and whom have never been treated for hepatitis with direct antiviral agents. participants will take maraviroc for 4 weeks in addition to their regular hiv antiretrovirals (art). the investigators will measure the hepatitis c viral load before, during, and after the 4-week maraviroc time.

Eligibility criteria:
inclusion criteria: 1. 18 years old 2. hepatitis c-infected without plans to undergo hepatitis c treatment for duration of the study 3. human immunodeficiency virus (hiv) infected 4. currently receiving anti-retroviral therapy with hiv viral load \<50 iu/ml for ≥ 12 months a. one virologic blip ≤ 400 copies/ml permissible within the 12 months 5. cd4 t cell counts \> 100 cells/mm3 6. non-cirrhotics and cirrhotics can be included 7. willing to sign informed consent exclusion criteria: 1. age \< 18 2. unable to comply with study visits, research study visits, or is planning to relocate during the study. 3. have any condition that the investigator considers a contraindication to study participation 4. pregnancy or breast feeding 5. decompensated liver disease (child-pugh c) 6. imminent treatment for hepatitis c infection 7. aspartate aminotransferase (ast) or alanine aminotransferase (alt) \>2.5 times the upper limits of normal 8. concomitant use of drugs known to impact or be impacted in terms of pharmacokinetics or drug-drug interactions with either raltegravir, dolutegravir, or maraviroc. this includes: * inducers of ugt1a1 (such as rifampin, phenytoin, phenobarbital rifabutin, st. john's wort) * cytochrome p3a inhibitors (such as ketoconazole, itraconazole, clarithromycin, nefazodone, and telithromycin) * cytochrome p3a inducers (such as rifampin, carbamazepine, phenobarbital and phenytoin)

Keywords: hepatitis c virus (hcv) maraviroc human immunodeficiency virus (hcv)
warmth and transcutaneous electrical nerve stimulation (tens) in improving cognitive functions in people with dementia

Conditions: Dementia

Summary: evidence showed that both tens and passive body heating are potential treatment strategies for improving cognitive functions in people with dementia. it is hypothesized that hat device (warmth +tens) over the 4 acupuncture points would induce a greater improvement in cognitive functions and behavioural symptoms when compared with other hat devices (warmth + placebo-tens; tens only; warmth alone) and control (hat device with no warmth and no tens).

acupuncture, a primary therapeutic method in traditional chinese medicine, has been used for patients with dementia to improve memory, orientation, calculation, and self-managing ability in patients having dementia and prevent decline of cognitive functions. results of animal studies have demonstrated that electroacupuncture on the head region is effective in managing the symptoms associated with dementia, including vascular dementia. a review of 8 studies on effects of tens on non-pain related cognitive and behavioural functioning in patients with alzheimer's disease and non-demented patients concluded that tens could improve memory, affective behaviour and rest-activity rhythm in patients having alzheimer's disease. passive body heating is another novel physical intervention strategy which potentially can relieve the symptoms of dementia. a previous study demonstrated that the attention function of 15 elderly, measured by the reaction time in the rapid visual processing test, improved after passive body heating via a thermal suit. moreover, 30 minutes of hot-water immersion improved the sleep quality in 13 people with vascular dementia.

Eligibility criteria:
inclusion criteria: 1. are currently diagnosed having alzheimer's disease, vascular dementia or mixed-type mild to major neurocognitive disorder based on the fifth edition of the diagnostic and statistical manual of mental disorders (dsm -5) by psychogeriatrician with more than 3 years of experience in dementia diagnosis; 2. are categorized in the mild or moderate degree of dementia based on the global deterioration scale; 3. have a stable drug intake for the past 3 months; 4. live with at least 1 caregiver in the community; 5. are able to follow simple instructions; 6. are able to give informed consent by them or their family members. exclusion criteria: 1. have unstable medical conditions or severe behavioural disturbances, which do not allow participation in the study as judged by the study psychogeriatrician, 2. have any additional medical, cardiovascular , orthopedic or cognitive conditions, such as having uncontrolled hypertension unstable angina and comorbid schizophrenia, that would hinder proper assessment and treatment. 3. use a cardiac pacemaker, 4. live in old age home, elderly home or care and attention homes, 5. receive long term nursing home placements of patients during the treatment phase

Keywords: transcutaneous electrical nerve stimulation cognitive memory
tart cherry juice and chronic disease risk

Conditions: CVD; Diabetes; Inflammation

Summary: in this study, the investigators recruited at-risk individuals (n=10) who were overweight (25.0-29.9 kg/m2) and obese (\> 30.0 kg/m2) and likely to exhibit one or more conditions associated with metabolic syndrome (mets). in this 10-week placebo-controlled 2 x 2 crossover dietary intervention, the investigators randomized participants (n=10) to consume 240 ml (8 ounces) daily of either placebo (artificial cherry-flavored, anthocyanin-free beverage) or authentic tcj for 4 weeks, followed by a 2-week washout period, then consumption of the alternate beverage for 4 weeks. in this study, the investigators determined the effect of tcj in at-risk participants on markers of inflammation, glycemia, and lipidemia.

in this study, the investigators recruited at-risk individuals (n=10) who were overweight (25.0-29.9 kg/m2) and obese (\> 30.0 kg/m2) and likely to exhibit one or more conditions associated with mets. participants were \>18 years of age, not pregnant, not diabetic, with no unresolved infections or diseases (diabetes, cvd, ibd, cancer and liver disease), and nonsmokers. histories of medication and dietary supplement use were collected and those taking anti-inflammatory or lipid-lowering medications were excluded. after enrollment, subjects were randomly assigned to consume daily either 240 ml (8 ounces) of authentic tcj (r.w. knudsen, chico, ca) or a placebo beverage (commercial fruit punch; great value, bentonville, ar) for 4 weeks. after a 2-week washout period, participants consumed the alternate beverage for 4 weeks in this 10-week 2x2 crossover, placebo-controlled dietary intervention. subsequently, the investigators determined the effect of tcj in at-risk participants on markers of lipidemia (hdl, ldl, triglycerides, vldl, total cholesterol), glycemia (fasting insulin and glucose, homa, quicki, mcauley indirect indices), and inflammation (hscrp, tnf-alpha, and esr).

Eligibility criteria:
inclusion criteria: * this study was a 12-week 2 x 2 crossover, randomized, placebo-controlled dietary intervention in overweight and obese participants (bmi\>25.0 kg/m2) who are more likely to exhibit \>1 of the 5 risk conditions associated with metabolic syndrome (mets). bmi was the minimal criterion for recruitment. exclusion criteria: * participants were \>18 years of age, not pregnant, not diabetic, with no unresolved infections or diseases (diabetes, cvd, ibd, cancer and liver disease), and nonsmokers. histories of medication and dietary supplement use were collected and those taking anti-inflammatory or lipid-lowering medications were excluded.

Keywords: obese overweight tart cherry juice
efficacy and safety of sage tablets compared to placebo in menopausal patients with hot flushes and sweating

Conditions: Menopausal Hot Flushes

Summary: sage tablets ( 3400 mg extract from fresh sage leaves, der 1:17) in a once daily application over 12 treatment weeks are compared against placebo in 200 menopausal patients with ≥ 5 hot flushes daily and a hyperhidrosis scale score ≥ 2


Eligibility criteria:
inclusion criteria: * menopausal since ≥ 1 year * ≥ 5 hot flushes /24 hours * hyperhidrosis scale score ≥ 2 exclusion criteria: * affections like asthma, copd, depression, diabetes, epilepsy, hyper- and hypothyreosis, malign tumours

Keywords: menopause, hot flushes, hot flashes, salvia, sage, sweating
the basophil activation test as a diagnostic tool in pediatric food allergy

Conditions: FOOD ALLERGY

Summary: background: the need for an oral food challenge (ofc) surrogate is growing in line with the continuous increase in the prevalence and severity of paediatric food allergy. the basophil activation test (bat) has recently been reported as a promising tool for predicting the outcome of ofc in children. objective: we make the hypothesis that bat might improve the sensitivity of food allergy diagnosis and spare part of current ofc in paediatric patients attending allergy departments in marseille aphm university hospitals. methods: bat will be performed in parallel with ofc in 100 paediatric patients receiving ofc during a diagnostic or follow-up procedure. expected results: good concordance of bat and ofc results leading to potential ofc replacement by bat in at least 50% of the study population


Eligibility criteria:
inclusion criteria: * age 0 - 18 years * attending la timone paediatric hospital for ofc * social insurance * parents and if possible child have received information and signed the consent form exclusion criteria: * patients not receiving an ofc * lack of social insurance * inability to understand the study information * unwilling to participate